title: Metreleptin: first global approval.
abstract: Metreleptin is an analogue of the human hormone leptin being developed by Amylin Pharmaceuticals (a subsidiary of Bristol-Myers Squibb) for the subcutaneous treatment of metabolic disorders including lipodystrophy. The compound is expected to improve insulin sensitivity, hypertriglyceridaemia and hyperglycaemia in patients with lipodystrophy who are unresponsive to conventional treatment. Metreleptin has been approved in Japan as a leptin therapy for the treatment of lipodystrophy. Amylin has also completed a submission for regulatory approval to the US FDA for metreleptin in the treatment of diabetes mellitus and/or hypertriglyceridaemia in patients with rare forms of lipodystrophy. Clinical development of the drug is also underway in the USA for the treatment of type 1 diabetes. Amgen was previously assessing the use of metreleptin as a treatment for amenorrhoea; however, it appears that development in this indication has been discontinued. This article summarizes the milestones in the development of metreleptin leading to this first approval for lipodystrophy.
authors.affiliation: Adis R & D Insight, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754 Auckland, New Zealand. dru@adis.com
authors.forename: Ken
authors.initials: K
authors.lastname: Chou
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Perry
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D004311:Double-Blind Method; D029721:Drosophila Proteins; D020690:GTPase-Activating Proteins; D006801:Humans; D020738:Leptin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008060:Lipodystrophy / Q000188:drug therapy*
chemical_list: D029721:Drosophila Proteins; D020690:GTPase-Activating Proteins; D020738:Leptin; C118002:RanGAP protein, Drosophila; C415771:metreleptin